MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$167,813K
Free Cash flow
-$19,588K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Proceeds from issuance of common...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-26,097
-22,253
-25,943
-20,171
Stock-based compensation expense
4,269
4,256
2,722
2,791
Depreciation expense
70
63
69
49
Loss on extinguishment of debt
-
-
0
0
Non-cash interest expense
-22
16
7
16
Non-cash lease expense
63
65
10
2
(gain) loss from changes in fair value on warrants
201
107
220
42
Loss on disposal of property and equipment
-
-
-23
-
Accretion of net investment discounts
563
306
1,623
-
Accounts receivable
-84
-60
254
-88
Prepaid expenses and other current assets
1,881
2,975
232
436
Other assets
-7
-1
-11
-10
Accounts payable
2,580
326
-2,307
3,645
Accrued expenses and other current liabilities
3,857
-3,843
1,354
-542
Deferred grant income
-
-
0
-
Deferred revenue
-1,828
437
-2,308
-1,538
Deferred grant income
-
-
-
0
Net cash used in operating activities
-19,260
-24,046
-28,251
-16,044
Purchase of property and equipment
328
26
112
22
Purchases of marketable securities
203,781
80,214
40,316
12,887
Maturities of marketable securities
39,595
33,487
26,000
25,750
Net cash used in investing activities
-164,514
-46,753
-14,428
12,841
Proceeds from series d issuance
-
-
0
0
Proceeds from issuance of common stock, net of underwriting discounts and commissions-Over Allotment Option
0
124,315
-
-
Underwritten offering issuance costs paid
-6
716
0
0
Proceeds from initial public offering, net of underwriting discounts and commissions
-
-
0
0
Issuance costs paid on initial public offering and private placement
-
-
0
0
Proceeds from issuance of common shares through private placement, net of placement agent fees
-
-
0
0
Proceeds from issuance of common stock through at-the-market facility, net of commissions
-
-
17,155
-
Proceeds from issuance of common stock, net of underwriting discounts and commissions-At The Market Program
15,852
-
-
-
Issuance costs paid on at-the market offering
215
-
64
-
Deferred offering costs paid
-10
91
292
44
Term loan principal payments
500
1,500
1,500
1,500
Payment of term loan final fee for loan maturity
660
-
-
-
Proceeds from issuance of common shares upon stock option exercises
1,473
1,707
714
0
Net cash provided by (used in) financing activities
15,966
123,715
16,013
-1,544
Effect of changes in exchange rate on cash and cash equivalents
-5
-27
-19
-10
Net decrease in cash and cash equivalents
-167,813
52,889
-26,685
-4,757
Cash and cash equivalents at end of period
241,777
188,888
215,573
354,349
Cash and cash equivalents at end of period
73,964
241,777
188,888
215,573
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock, net of...
$15,852K
Proceeds from issuance of
common shares upon...
$1,473K
Deferred offering costs
paid
-$10K
Underwritten offering
issuance costs paid
-$6K
Net cash provided by
(used in) financing...
$15,966K
(632.20%↑ Y/Y)
Canceled cashflow
$1,375K
Net decrease in cash
and cash...
-$167,813K
(-25.22%↓ Y/Y)
Canceled cashflow
$15,966K
Maturities of marketable
securities
$39,595K
(365.82%↑ Y/Y)
Stock-based compensation
expense
$4,269K
(-30.90%↓ Y/Y)
Accrued expenses and
other current...
$3,857K
(191.31%↑ Y/Y)
Accounts payable
$2,580K
(569.09%↑ Y/Y)
(gain) loss from
changes in fair value on...
$201K
(518.75%↑ Y/Y)
Accounts receivable
-$84K
(-113.93%↓ Y/Y)
Depreciation expense
$70K
(-26.32%↓ Y/Y)
Non-cash lease expense
$63K
(-44.25%↓ Y/Y)
Other assets
-$7K
(-133.33%↓ Y/Y)
Payment of term loan
final fee for loan...
$660K
Term loan principal
payments
$500K
(-83.33%↓ Y/Y)
Issuance costs paid on
at-the market offering
$215K
Net cash used in
investing activities
-$164,514K
(-75.71%↓ Y/Y)
Net cash used in
operating activities
-$19,260K
(48.41%↑ Y/Y)
Canceled cashflow
$39,595K
Canceled cashflow
$11,131K
Effect of changes in
exchange rate on cash and...
-$5K
(91.38%↑ Y/Y)
Purchases of marketable
securities
$203,781K
(100.68%↑ Y/Y)
Net loss
-$26,097K
(24.34%↑ Y/Y)
Purchase of property and
equipment
$328K
(-43.93%↓ Y/Y)
Prepaid expenses and
other current assets
$1,881K
(80.00%↑ Y/Y)
Deferred revenue
-$1,828K
(36.97%↑ Y/Y)
Accretion of net
investment discounts
$563K
Non-cash interest
expense
-$22K
(-115.71%↓ Y/Y)
Buy us a coffee
BioAge Labs, Inc. (BIOA)
BioAge Labs, Inc. (BIOA)